Logo
x

Search category

Subscribe Now

Travere Therapeutics

Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Approval for the Reduction of Proteinuria in IgA Nephropathy

Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Approval for the Reduction of Proteinuria in IgA Nephropathy

  • February 21, 2023
Travere Therapeutics Reports US FDA Acceptance of NDA and Priority Review for Sparsentan to Treat IgA Nephropathy

Travere Therapeutics Reports US FDA Acceptance of NDA and Priority Review for Sparsentan to Treat IgA Nephropathy

  • May 17, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.